SCH-442,416

SCH-442,416
Names
	IUPAC name 2-(2-furyl)-7-[3-(4-methoxyphenyl)propyl]-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine
	Other names SCH-442,416
Identifiers
CAS Number	316173-57-6 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL136689 ;
ChemSpider	8843413 ;
IUPHAR/BPS	3283;
PubChem CID	10668061;
UNII	ZMC4G1W59S ;
CompTox Dashboard (EPA)	DTXSID70443263 ;
	InChI InChI=1S/C20H19N7O2/c1-28-14-8-6-13(7-9-14)4-2-10-26-18-15(12-22-26)19-23-17(16-5-3-11-29-16)25-27(19)20(21)24-18/h3,5-9,11-12H,2,4,10H2,1H3,(H2,21,24) Key: AEULVFLPCJOBCE-UHFFFAOYSA-N ; InChI=1/C20H19N7O2/c1-28-14-8-6-13(7-9-14)4-2-10-26-18-15(12-22-26)19-23-17(16-5-3-11-29-16)25-27(19)20(21)24-18/h3,5-9,11-12H,2,4,10H2,1H3,(H2,21,24) Key: AEULVFLPCJOBCE-UHFFFAOYAA;
	SMILES n1n3c(nc4c(c3nc1c2occc2)cnn4CCCc5ccc(OC)cc5)N;
Properties
Chemical formula	C20H19N7O2
Molar mass	389.410
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

SCH-442,416 is a highly selective adenosine A_2a subtype receptor antagonist. It is widely used in its ¹¹C radiolabelled form to map the distribution of A_2a receptors in the brain, where they are mainly found in the striatum, nucleus accumbens, and olfactory tubercle.^[1] Given its distribution in the brain, A_2a receptors have been investigated for the treatment of various neurological disorders, and SCH-442,416 has shown promise in treatment of depression,^[2] Parkinson's disease,^[3] and catalepsy.^[4]

References

^ Moresco RM, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, et al. (April 2005). "In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416". European Journal of Nuclear Medicine and Molecular Imaging. 32 (4): 405–13. doi:10.1007/s00259-004-1688-5. PMID 15549298.
^ El Yacoubi M, Costentin J, Vaugeois JM (December 2003). "Adenosine A2A receptors and depression". Neurology. 61 (11 Suppl 6): S82-7. doi:10.1212/01.wnl.0000095220.87550.f6. PMID 14663017.
^ Matsuya T, Takuma K, Sato K, Asai M, Murakami Y, Miyoshi S, et al. (March 2007). "Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model". Journal of Pharmacological Sciences. 103 (3): 329–32. doi:10.1254/jphs.scz070058. PMID 17341841.
^ Mihara T, Noda A, Arai H, Mihara K, Iwashita A, Murakami Y, et al. (July 2008). "Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect". Journal of Nuclear Medicine. 49 (7): 1183–8. doi:10.2967/jnumed.108.051474. PMID 18552135.

External links

Molecular Imaging and Contrast Agent Database: SCH-442,416

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] Moresco RM, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, et al. (April 2005). "In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416". European Journal of Nuclear Medicine and Molecular Imaging. 32 (4): 405–13. doi:10.1007/s00259-004-1688-5. PMID 15549298.

[2] El Yacoubi M, Costentin J, Vaugeois JM (December 2003). "Adenosine A2A receptors and depression". Neurology. 61 (11 Suppl 6): S82-7. doi:10.1212/01.wnl.0000095220.87550.f6. PMID 14663017.

[3] Matsuya T, Takuma K, Sato K, Asai M, Murakami Y, Miyoshi S, et al. (March 2007). "Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model". Journal of Pharmacological Sciences. 103 (3): 329–32. doi:10.1254/jphs.scz070058. PMID 17341841.

[4] Mihara T, Noda A, Arai H, Mihara K, Iwashita A, Murakami Y, et al. (July 2008). "Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect". Journal of Nuclear Medicine. 49 (7): 1183–8. doi:10.2967/jnumed.108.051474. PMID 18552135.

[1]

[2]

[3]

[4]